Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407
Wanda L Salzer, Tamekia L Jones, Meenakshi Devidas, Joanne M Hilden, Naomi Winick, Stephen Hunger, William L Carroll, Bruce Camitta, ZoAnn E Dreyer, Wanda L Salzer, Tamekia L Jones, Meenakshi Devidas, Joanne M Hilden, Naomi Winick, Stephen Hunger, William L Carroll, Bruce Camitta, ZoAnn E Dreyer
Abstract
Background: Infants (<366 days of age) with acute lymphoblastic leukemia (ALL) have a poor prognosis. Most treatment failures occur within 6-9 months of diagnosis, primarily from relapse.
Procedure: The Children's Oncology Group P9407 study was designed to test if early intensified treatment would improve outcome for infants with ALL. Due to a significant number of early deaths (< 90 days from enrollment), Induction therapy was amended three times. Cohorts 1 + 2 (n = 68), received identical Induction therapy except for reduced daunorubicin dose in Cohort 2. Cohort 3 (n = 141) received prednisone (40 mg/m(2)/day) instead of dexamethasone (10 mg/m(2)/day) and short infusion daunorubicin (30 minutes) instead of continuous infusion (48 hours), as well as additional supportive care measures throughout therapy.
Results: Early deaths occurred in 17/68 (25%) infants in Cohorts 1 + 2 and 8/141 (5.7%) infants in Cohort 3 (P < 0.0001). Among infants ≤90 days of age at diagnosis, early death occurred in 10/17 (58.8%) in Cohorts 1 + 2 and 4/27 (14.8%) in Cohort 3 (P = 0.006). Among infants >90 days of age at diagnosis, early death occurred in 7/51 (13.7%) in Cohorts 1 + 2 and 4/114 (3.5%) in Cohort 3 (P = 0.036). Bacterial, viral, and fungal infections were more common in Cohorts 1 + 2 versus Cohort 3.
Conclusions: Early morbidity and mortality for infants with ALL were reduced by substitution of prednisone (40 mg/m(2)/day) for dexamethasone (10 mg/m(2)/day), the delivery of daunorubicin over 30 minutes instead of a continuous infusion for 48 hours, and the provision of more specific supportive care measures.
Conflict of interest statement
Conflict of interest: Nothing to declare.
Copyright © 2012 Wiley Periodicals, Inc.
Figures

Source: PubMed
다가오는 임상 시험
-
Artvin Coruh University아직 모집하지 않음샤르코 마리 투스병(CMT)터키 (Türkiye)
-
University of Management and Technology Lahore아직 모집하지 않음
-
Regeneron Pharmaceuticals모병
-
Kirsehir Ahi Evran Universitesi아직 모집하지 않음아동 학대 | 간호교육 | 아동 방치 | 아동 성적 학대
-
Lokman Hekim University아직 모집하지 않음
-
Imagion Biosystems, Inc.모병
-
Ankara City Hospital Bilkent모병출산에 대한 두려움 | 제왕절개 | LABOR PAİN터키 (Türkiye)
-
Örebro University, Sweden모병
-
Cairo University아직 모집하지 않음
-
Indiana University모병임신 예방 | 남성 피임법 | 피임 장치 | Prevention of Semen Exposure During Intercourse미국
-
Tianjin Medical University Cancer Institute and...아직 모집하지 않음맨틀 세포 림프종(MCL) | 재발성/난치성 맨틀세포림프종 (MCL)중국